Takeda Pharmaceutical Company Limited (NYSE:TAK) Position Trimmed by Summit Global Investments

Summit Global Investments lessened its holdings in shares of Takeda Pharmaceutical Company Limited (NYSE:TAK - Free Report) by 51.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The fund owned 350,739 shares of the company's stock after selling 378,461 shares during the period. Summit Global Investments' holdings in Takeda Pharmaceutical were worth $5,215,000 as of its most recent filing with the Securities and Exchange Commission (SEC).

A number of other institutional investors and hedge funds also recently added to or reduced their stakes in TAK. Farther Finance Advisors LLC increased its stake in shares of Takeda Pharmaceutical by 123.6% during the fourth quarter. Farther Finance Advisors LLC now owns 3,575 shares of the company's stock worth $47,000 after purchasing an additional 1,976 shares in the last quarter. Crowley Wealth Management Inc. acquired a new position in Takeda Pharmaceutical during the fourth quarter worth about $52,000. Cromwell Holdings LLC acquired a new position in Takeda Pharmaceutical in the 4th quarter valued at about $61,000. Venturi Wealth Management LLC boosted its holdings in Takeda Pharmaceutical by 554.7% in the 4th quarter. Venturi Wealth Management LLC now owns 5,028 shares of the company's stock valued at $67,000 after purchasing an additional 4,260 shares during the last quarter. Finally, Lindbrook Capital LLC boosted its holdings in Takeda Pharmaceutical by 65.0% in the 4th quarter. Lindbrook Capital LLC now owns 5,151 shares of the company's stock valued at $68,000 after purchasing an additional 2,029 shares during the last quarter. Hedge funds and other institutional investors own 9.17% of the company's stock.

Takeda Pharmaceutical Stock Down 0.9%

Shares of NYSE:TAK traded down $0.13 during trading hours on Tuesday, reaching $14.95. The stock had a trading volume of 441,021 shares, compared to its average volume of 1,992,917. The firm's 50 day moving average is $14.66 and its 200-day moving average is $14.06. Takeda Pharmaceutical Company Limited has a 1 year low of $12.57 and a 1 year high of $15.43. The company has a debt-to-equity ratio of 0.63, a quick ratio of 0.72 and a current ratio of 1.31. The stock has a market capitalization of $47.57 billion, a price-to-earnings ratio of 37.38, a P/E/G ratio of 0.24 and a beta of 0.26.

Takeda Pharmaceutical (NYSE:TAK - Get Free Report) last released its earnings results on Thursday, May 8th. The company reported $0.16 EPS for the quarter, missing the consensus estimate of $0.24 by ($0.08). Takeda Pharmaceutical had a return on equity of 9.39% and a net margin of 4.53%. The firm had revenue of $7.34 billion during the quarter, compared to analyst estimates of $8.02 billion. Research analysts predict that Takeda Pharmaceutical Company Limited will post 1.64 earnings per share for the current fiscal year.

Wall Street Analyst Weigh In

Separately, Morgan Stanley upgraded shares of Takeda Pharmaceutical from an "equal weight" rating to an "overweight" rating in a report on Wednesday, April 2nd.

Takeda Pharmaceutical Company Profile

Takeda Pharmaceutical Company Limited engages in the research, development, manufacture, marketing, and out-licensing of pharmaceutical products in Japan and internationally. It offers pharmaceutical products in the areas of gastroenterology, rare diseases, plasma derived therapies, immunology, oncology, and neuroscience.